[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532089":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":35,"locations":46,"responsibleParty":66,"collaborators":44,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":44,"enrollmentInfo":80,"targetDuration":44,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":44,"overallStatus":49,"whyStopped":44,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"St. Mary's Research Center, Canada","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"1)Standard care: 1G TXA IV","ACTIVE_COMPARATOR","1 gm TA IV given prior to incision and 1G TXA IV during cementation or closure",[13],"Drug: Tranexamic acid",{"label":15,"type":10,"description":16,"interventionNames":17},"2) Standard + 1G oral TXA - 0 and 8 hours post-operatively","Standard + 1G oral TXA given at 0 and 8 hours post-operatively",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"3) Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively","Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Tranexamic acid","This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA",[9,15,19],[29],"CYKLOKAPRON",[31],{"name":32,"affiliation":33,"role":34},"Jennifer Mutch, MDCM, FRCSC","St. Mary's Hospital Centre","PRINCIPAL_INVESTIGATOR",[36,41],{"name":32,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","514 345 3511","3282","j.mutch.ortho@gmail.com",{"name":42,"role":37,"phone":43,"phoneExt":44,"email":45},"Sandhya Baskaran, MBA, M.ED","514 239 0042",null,"sandhya.baskaran.comtl@ssss.gouv.qc.ca",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"St. Mary's Hospital Center","RECRUITING","Montreal","Quebec","H3T 1M5","Canada","CA",{"type":56,"coordinates":57},"Point",[58,59],-73.58781,45.50884,{"lat":59,"lon":58},[62,63,64],{"name":32,"role":37,"phone":38,"phoneExt":39,"email":40},{"name":42,"role":37,"phone":43,"phoneExt":44,"email":45},{"name":65,"role":34,"phone":44,"phoneExt":44,"email":44},"Jennifer Mutch, MD FRCP",{"type":34,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Anthony Albers, MD","Director of Orthopaedic Research, Orthopaedic Surgeon","100532089","tranexamic-acid-use-on-pain-mobility-and-bleeding-following-total-hip-and-total-knee-arthroplasty-100532089",false,"NCT06208267","Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty","The Impact of Additional Post-operative Doses of Tranexamic Acid on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty: A Randomized Controlled Trial","TXA","Inclusion Criteria:\n\n° All adults undergoing primary TKA and THA at St-Mary's Hospital\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Known hypersensitivity or allergy to TXA\n* Previous history of thromboembolic disease\n* Active malignancy (all current cancers other than local skin cancer)\n* Significant renal disease (hematuria, dialysis, kidney transplant)\n* History of convulsions\n* Known defective colour vision\n* Inability or unwillingness to use MyMobility app\n* Unable to communicate in French or English",true,"ALL","18 Years",{"count":81,"type":82},210,"ESTIMATED","INTERVENTIONAL",[85],"NA","Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty.\n\nThe efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies. Its wide range of applications, combined with its favourable risk-benefit ratio, has led to the incorporation of TXA into clinical guidelines and protocols worldwide.\n\nThis RCT aims to compare the current standard dosing for TXA to additional TXA doses given orally post-operatively for THA and TKA patients. The goal is to compare the following between study groups: visible bleeding on post-operative dressing, mobilization (steps, amount of time moving around), pain (visual analog scale), function (Oxford hip and knee scales) and ROM at four to six weeks.",[88],"Postoperative Bleeding","2026-04-22",{"date":91,"type":92},"2026-04-28","ACTUAL",{"date":94,"type":92},"2025-08-20",{"date":96,"type":82},"2027-07",{"name":5,"class":6},1]